Full Text:   <3055>

CLC number: R735

On-line Access: 

Received: 2009-03-03

Revision Accepted: 2009-07-31

Crosschecked: 2009-08-18

Cited: 18

Clicked: 6006

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2009 Vol.10 No.9 P.675-682


DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters

Author(s):  Qi-lian LIANG, Bi-rong WANG, Guo-hong LI

Affiliation(s):  Department of Medical Oncology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China

Corresponding email(s):   lianqilian@gdmc.edu.cn

Key Words:  Death decoy receptor 3 (DcR3), Survivin, Colorectal carcinoma

Qi-lian LIANG, Bi-rong WANG, Guo-hong LI. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters[J]. Journal of Zhejiang University Science B, 2009, 10(9): 675-682.

@article{title="DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters",
author="Qi-lian LIANG, Bi-rong WANG, Guo-hong LI",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters
%A Qi-lian LIANG
%A Bi-rong WANG
%A Guo-hong LI
%J Journal of Zhejiang University SCIENCE B
%V 10
%N 9
%P 675-682
%@ 1673-1581
%D 2009
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B0920077

T1 - DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters
A1 - Qi-lian LIANG
A1 - Bi-rong WANG
A1 - Guo-hong LI
J0 - Journal of Zhejiang University Science B
VL - 10
IS - 9
SP - 675
EP - 682
%@ 1673-1581
Y1 - 2009
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B0920077

Objective: To investigate the expression of death decoy receptor 3 (DcR3) and survivin in colorectal carcinoma. Methods: Tumor and normal tissues were taken from a total of 100 colorectal carcinoma patients during surgery, and the expression of DcR3 and survivin was examined by immunohistochemistry, Western blotting, and reverse transcription-polymerase chain reaction (RT-PCR) analyses. Results: RT-PCR showed that the expression levels of DcR3 mRNA (0.846±0.242, P<0.01) and survivin mRNA (0.7835±0.2392, P<0.01) in colorectal cancer tissues were significantly higher than those in adjacent normal tissues. Western blotting showed that the expression levels of DcR3 protein (0.795±0.261, P<0.01) and survivin protein (0.6765±0.1351, P<0.01) in tumor tissues were significantly higher than those in non-cancer tissues. The immunohistochemical streptavidin-peroxidase (SP) method showed that the positive expression rates of DcR3 and survivin were 67.0% and 58.0% in colorectal cancer tissues, and 18.0% and 3.0% in non-cancerous colorectal tissues (P<0.05), respectively. The positive correlations of DcR3 (P<0.01) and survivin (P<0.01) to the differentiation of colorectal carcinoma cells, lymph node metastasis, and pathological stage were observed. The expression of DcR3 and survivin was found to be positively correlated to clinicopathologic parameters of colorectal carcinoma. Conclusion: The overexpressed DcR3 and survivin in colorectal cancer may contribute to the development of the cancer. The monitoring of these two proteins may be useful for the diagnosis, differentiation, metastasis, and determination of stages of colorectal carcinoma.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1] Bai, C., Connolly, B., Metzker, M.L., Hilliard, C.A., Liu, X., Sandig, V., Soderman, A., Galloway, S.M., Liu, Q., Austin, C.P., Caskey, C.T., 2000. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl. Acad. Sci. USA, 97(3): 1230-1235.

[2] Chang, P.M., Chen, P.M., Hsieh, S.L., Tzeng, C.H., Liu, J.H., Chiou, T.J., Wang, W.S., Yen, C.C., Gau, J.P., Yang, M.H., 2008. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int. J. Oncol., 33(3):549-554.

[3] Chen, C., Zhang, C., Zhuang, G., Luo, H., Su, J., Yin, P., Wang, J., 2008. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Cancer Invest., 26(10):965-974.

[4] Chen, P.H., Yang, C.R., 2008. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappaB-dependent pathway. J. Immunol., 181(12):8441-8449.

[5] Connor, J.P., Felder, M., 2008. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol. Oncol., 111(2):330-335.

[6] Elnemr, A., Ohta, T., Yachie, A., Kayahara, M., Kitagawa, H., Fujimura, T., Ninomiya, I., Fushida, S., Nishimura, G.I., Shimizu, K., Miwa, K., 2001. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int. J. Oncol., 18(2): 311-316.

[7] Fayad, R., Brand, M.I., Stone, D., Keshavarzian, A., Qian, L., 2006. Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. Eur. J. Immunol., 36(8):2215-2222.

[8] Gill, R.M., Coleman, N.M., Hunt, J.S., 2007. Differential cellular expression of LIGHT and its receptors in early gestation human placentas. J. Reprod. Immunol., 74(1-2): 1-6.

[9] Hayashi, S., Miura, Y., Nishiyama, T., Mitani, M., Tateishi, K., Sakai, Y., Hashiramoto, A., Kurosaka, M., Shiozawa, S., Doita, M., 2007. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum., 56(4):1067-1075.

[10] Inoue, Y., Morinaga, A., Takizawa, F., Saito, T., Endo, M., Haruta, C., Nakai, T., Moritomo, T., Nakanishi, T., 2008. Molecular cloning and preliminary expression analysis of banded dogfish (Triakis scyllia) TNF decoy receptor 3 (TNFRSF6B). Fish Shellfish Immunol., 24(3):360-365.

[11] Kim, S., Fotiadu, A., Kotoula, V., 2005. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin. Immunol., 115(3):286-294.

[12] Lee, C.S., Hu, C.Y., Tsai, H.F., Wu, C.S., Hsieh, S.L., Liu, L.C., Hsu, P.N., 2008. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin. Exp. Immunol., 151(3):383-390.

[13] Li, D.L., Yu, Q.Z., Feng, X.G., Li, M., Lu, W., 2005. The measures and experiences on actualizing “The Diagnosis and Treatment Criterion for Common Cancer in China” in Shanghai. Bull. Chin. Cancer, 14(1):3-7 (in Chinese).

[14] Macher-Goeppinger, S., Aulmann, S., Wagener, N., Funke, B., Tagscherer, K.E., Haferkamp, A., Hohenfellner, M., Kim, S., Autschbach, F., Schirmacher, P., Roth, W., 2008. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia, 10(10):1049-1056.

[15] Mild, G., Bachmann, F., Boulay, J.L., Glatz, K., Laffer, U., Lowy, A., Metzger, U., Reuter, J., Terracciano, L., Herrmann, R., Rochlitz, C., 2002. DcR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int. J. Cancer, 102(3):254-257.

[16] Pitti, R.M., Marsters, S.A., Lawrence, D.A., Roy, M., Kischkel, F.C., Dowd, P., Huang, A., Donahue, C.J., Sherwood, S.W., Baldwin, D.T., et al., 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 396(17):699-703.

[17] Roth, W., Isenmann, S., Nakamura, M., Platten, M., Wick, W., Kleihues, P., Bahr, M., Ohgaki, H., Ashkenazi, A., Weller, M., 2001. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res., 61(6):2759-2765.

[18] Sarela, A.I., Macadam, R.C., Farmery, S.M., Markham, A.F., Guillou, P.J., 2000. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut, 46(5):645-650.

[19] Sarela, A.I., Verbeke, C.S., Ramsdale, J., Davies, C.L., Markham, A.F., Guillou, P.J., 2002. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br. J. Cancer, 86(6):886-892.

[20] Shen, H.W., Wu, Y.L., Peng, S.Y., 2003. Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof. Natl. Med. J. China, 83(9):744-747 (in Chinese).

[21] Takahama, Y., Yamada, Y., Emoto, K., Fujimoto, H., Takayama, T., Ueno, M., Uchida, H., Hirao, S., Mizuno, T., Nakajima, Y., 2002. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric. Cancer, 5(2):61-68.

[22] Tamm, I., Wang, Y., Sausville, E., Scudiero, D.A., Vigna, N., Oltersdorf, T., Reed, J.C., 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 58(23):5315-5320.

[23] Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., Tanigawa, N., 2000. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res., 6(1):127-134.

[24] Wu, Y., Han, B., Sheng, H., Lin, M., Moore, P.A., Zhang, J., Wu, J., 2003. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer, 105(5):724-732.

[25] Xia, C., Xu, Z., Yuan, X., Uematsu, K., You, L., Li, K., Li, L., McCormick, F., Jablons, D.M., 2002. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol. Cancer Ther., 1(9):687-694.

[26] Zhu, X.D., Lin, G.J., Qian, L.P., Chen, Z.Q., 2003. Expression of survivin in human gastric carcinoma and gastric carcinoma model of rats. World J. Gastroenterol., 9(7): 1435-1438.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE